[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 240
Citations 0
Comment & Response
December 21, 2018

Consideration of Costs and Open-Label Studies of Erenumab—Reply

Author Affiliations
  • 1Division of Headache, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Neurol. 2019;76(2):236-237. doi:10.1001/jamaneurol.2018.4141

In Reply Charles disagrees with our recommendation that less expensive preventive treatments for migraine should be tried before the new calcitonin gene–related peptide (CGRP) and CGRP receptor monoclonal antibodies.1 The existing scientific evidence suggests that the new antibody treatments are not more effective than many existing therapies.2 In the absence of clearly superior efficacy, prudence suggests that less expensive treatments of comparable benefit and with a well-understood safety profile should be used first. The monoclonal antibodies appeared to be well-tolerated in trials, but accumulating experience since their approval suggests that adverse events are more common in clinical use. In particular, severe constipation, nausea, and fatigue have emerged as treatment-limiting adverse effects for some patients.3,4